Clinical Trial Detail

NCT ID NCT03241186
Title Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Robert R. McWilliams, MD
Indications

mucosal melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: senior adult

No variant requirements are available.